中文
About
中文
取消
GET TO KNOW US
KNOW
About us
Sperogenix Therapeutics is a platform company dedicated to developing and commercializing rare disease therapeutics in China. With prioritized therapeutic areas, such as pulmonary vascular disorders, neuromuscular diseases, and inherited metabolic diseases, Sperogenix is dedicated to establishing an innovative commercial model tailored to the China rare disease field, in order to provide affordable and reliable products and services to Chinese physicians and patients. Sperogenix was founded in 2019 and is backed by biopharma industry blue chip investors including Lilly Asia Ventures and Morningside Ventures.
Vision, Mission & Values
Vision
Strive to become the respected leading rare diseases company with commercial success in China
Mission
Committed to providing advanced products and solutions for Chinese rare diseases patients, narrowing the gap between China and developed countries and regions in diagnosis and treatment, and meeting the unmet medical needs in the field of rare diseases in China.
Values
Patients and physicians centerd. High standard of responsibility and ethics. Unremitting learning and innovation
Strategies
BUSINESS DEVELOPMENT
Meet the huge unmet demands with advanced treatment
CLINICAL DEVELOPMENT
Accelerate both global and local product approval and launch
CUSTOMER ENGAGEMENT
Establish a promising future for product value maximization
Scientific Advisory Board
Hanlan LIU PhD., MBA
SAB Chair
Khazal PARADIS MDCM
SAB Member
Renato SKERLJ PhD.
SAB Member
Ling SU PhD.
SAB Member
Executive Management
Zhiyu YAN
Co-Founder, Chairman & Chief Executive Officer
Xiaohui WANG
Co-Founder, Chief Business Officer & Chief Operating Officer
Hanlan LIU PhD., MBA
Chief Scientific Officer & Chief Development Officer
Investors
Lilly Asia Ventures
Lilly Asia Ventures (LAV) is a leading biomedical venture capital firm, with offices in Shanghai, Hong Kong, and Palo Alto. LAV's vision is to become the trusted partner for exceptional entrepreneurs seeking smart capital and to build great companies developing breakthrough products that treat diseases and improve human health.
Morningside Ventures
Morningside Group was founded in 1986, by the Chan family of Hong Kong, to make private equity and venture capital investments. The group is managed by investment professionals who are entrepreneurial, have deep industry knowledge and are effective in the local environment in which they operate. In addition to its investment activities, Morningside Group is strongly committed to social responsibility.
Contact US
Beijing
address: A-216, No.56 Dongzhimen Wai Xie St. Chaoyang, Beijing 100027, China
tel: +86 10 6462 0528
Shanghai
address: Room 1502, Building C Poly West Bund Center, No.275, Ruiping Rd, Xuhui Disrict, Shanghai 200232, China
tel: +86 21 5456 5990
Home
About
Patients
Health Care Professionals
News
Social Responsibilities
Careers
Copyright Sperogenix Therapeutics Limited © 2020 All rights reserved. 京ICP备19059578号